North America And Europe Celiac Disease Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
 예측 기간 |
2024 –2031 |
 시장 규모(기준 연도) |
USD 94,325.34 Thousand |
 시장 규모(예측 연도) |
USD 193,364.33 Thousand |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
북미 및 유럽 셀리악병 시장, 치료 유형(코르티코스테로이드, 면역억제제 및 기타), 질병 유형(전형적 셀리악병, 비전형적 셀리악병, 내성 셀리악병, 잠재적 셀리악병 및 피부염 포진형), 약물 유형(제네릭 및 브랜드), 처방 유형(처방 및 일반 의약품), 투여 형태(정제, 캡슐, 주사 및 기타), 투여 경로(경구, 정맥 주사 및 국소), 인구 유형(어린이, 성인 및 노인), 최종 사용자(병원, 진료소, 진단 센터, 가정 간병 시설 및 기타), 유통 채널(병원 약국, 소매 약국, 온라인 약국 및 기타) – 2031년까지의 산업 동향 및 예측.
북미 및 유럽 셀리악병 시장 분석 및 통찰력
북미와 유럽의 셀리악병 시장 역학은 이 질환의 유병률 증가, 진단 기술의 발전, 글루텐 없는 제품에 대한 시장 확대와 같은 요인에 의해 영향을 받습니다. 이 지역의 의료 서비스 제공자는 인지도를 높이고, 검진을 실시하고, 치료 전략을 구현하는 데 중요한 역할을 합니다. 또한, 일반 대중 사이에서 라이프스타일 선택으로서 글루텐 없는 식단에 대한 관심이 커지면서 시장이 확대되고 있습니다.
전반적으로 북미와 유럽의 셀리악병 시장은 이 자가면역 질환에 걸린 사람들의 삶을 개선하기 위한 인식, 진단 및 연구 이니셔티브의 역동적인 상호 작용을 반영합니다. 그러나 시장은 셀리악병 치료에 사용되는 약물과 관련된 질병의 복잡성 및 부작용과 같은 과제에 직면합니다.
북미 셀리악병 시장은 2024년부터 2031년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2024년부터 2031년까지의 예측 기간 동안 9.8%의 CAGR로 성장하고 있으며 2023년 94,325.34천 달러에서 2031년까지 193,364.33천 달러에 도달할 것으로 분석했습니다.
유럽 셀리악병 시장은 2024년부터 2031년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2024년부터 2031년까지의 예측 기간 동안 8.8%의 CAGR로 성장하고 있으며 2023년 78,786.35천 달러에서 2031년까지 150,949.09천 달러에 도달할 것으로 분석했습니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2024년부터 2031년까지 |
|
기준 연도 |
2023 |
|
역사적 연도 |
2022 (2020-2021년까지 맞춤 설정 가능) |
|
양적 단위 |
매출(USD 천), 볼륨(단위) |
|
다루는 세그먼트 |
치료 유형(코르티코스테로이드, 면역억제제 및 기타), 질병 유형(전형적 셀리악병, 비전형적 셀리악병, 내성 셀리악병, 잠재적 셀리악병 및 피부염 포진형), 약물 유형(제네릭 및 브랜드), 처방 유형(처방 및 일반 의약품), 투여 형태(정제, 캡슐, 주사 및 기타), 투여 경로(경구, 정맥 및 국소), 인구 유형(어린이, 성인 및 노인), 최종 사용자(병원, 진료소, 진단 센터, 가정 간병 시설 및 기타), 유통 채널(병원 약국, 소매 약국, 온라인 약국 및 기타) |
|
적용 국가 |
미국, 캐나다, 멕시코, 독일, 프랑스, 이탈리아, 스페인, 영국, 스위스, 네덜란드, 러시아, 터키, 폴란드, 스웨덴, 벨기에, 덴마크, 핀란드, 노르웨이 및 기타 유럽 국가 |
|
시장 참여자 포함 |
Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals(Bausch Health Companies Inc.의 자회사), Tillotts Pharma AG, GSK plc., ImmunogenX, Inc., Janssen Pharmaceuticals, Inc.(Johnson & Johnson Services, Inc.의 자회사), Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., AstraZeneca, Novartis AG, AdvaCare Pharma, ANOKION, Topas Therapeutics, Immunic Therapeutics 및 Equillium Bio. 등 |
시장 정의
셀리악병은 밀, 보리, 호밀에 들어 있는 단백질인 글루텐을 섭취했을 때 비정상적인 면역 반응을 보이는 만성 자가면역 질환입니다. 셀리악병이 있는 사람이 글루텐을 섭취하면 면역 체계가 실수로 소장 점막을 공격하여 영양소 흡수를 담당하는 손가락 모양의 돌기인 융모에 염증과 손상이 발생합니다. 이 면역 반응은 복통, 설사, 체중 감소, 피로, 영양 결핍을 포함한 다양한 위장관 및 전신 증상을 유발합니다.
셀리악병 진단에는 종종 특정 항체를 검출하기 위한 혈액 검사와 확진 장 생검을 병행하는 것이 포함됩니다. 셀리악병에 대한 일차적이고 평생 치료는 엄격한 글루텐 없는 식단입니다. 셀리악병이 있는 개인은 식단에서 글루텐을 제거함으로써 증상을 관리하고, 장 치유를 촉진하고, 합병증을 예방할 수 있습니다. 글루텐 없는 라이프스타일을 고수하는 것이 중요합니다. 소량의 글루텐도 면역 반응을 유발하고 상태를 악화시킬 수 있기 때문입니다. 셀리악병은 모든 연령대의 사람들에게 영향을 미칠 수 있으며, 평생 질환이지만 적절하게 관리하면 개인이 건강하고 만족스러운 삶을 살 수 있습니다.
북미 및 유럽 셀리악병 시장 동향
운전자
- 증가하는 셀리악병 유병률
셀리악병은 밀, 보리, 호밀에 들어 있는 단백질인 글루텐에 대한 불내성을 특징으로 하는 자가면역 질환입니다. 셀리악병의 유병률은 최근 몇 년 동안 증가하고 있으며, 여러 요인이 이러한 증가에 기여합니다.
서구화된 식단이 만연한 북미와 유럽에서 글루텐 소비 증가로의 전환은 시장 성장을 더욱 증폭시킵니다. 따라서 셀리악병의 유병률 증가는 북미와 유럽 셀리악병 시장의 원동력이 될 것으로 예상됩니다.
- 글루텐 함유 제품에 대한 수요 증가
글루텐 함유 제품은 글루텐을 자연적으로 함유한 재료로 만들어집니다. 여기에는 빵, 파스타, 페이스트리, 시리얼과 같은 밀 기반 제품이 포함됩니다. 보리와 호밀 기반 제품에도 글루텐이 포함되어 있습니다.
베이킹에서 글루텐은 빵과 기타 구운 식품의 부풀림과 질감에 기여합니다. 이러한 재료는 구운 식품에서 파스타, 특정 소스 및 가공 식품에 이르기까지 다양한 식품에 사용됩니다.
글루텐 함유 제품에 대한 수요는 소비자 선호도, 요리 전통 및 특정 식품의 문화적 중요성으로 인해 북미와 유럽에서 여전히 강세를 유지하고 있습니다. 이는 이 지역에서 전통적인 글루텐이 풍부한 식품에 대한 광범위한 소비자 선호도를 반영하며, 이는 셀리악병의 위험을 더욱 증가시킬 것입니다. 따라서 글루텐 함유 제품에 대한 수요 증가는 북미와 유럽 셀리악병 시장의 원동력이 될 것으로 예상됩니다.
제지
- 셀리악병의 복잡성
셀리악병은 밀, 보리, 호밀 및 그 파생물에서 발견되는 단백질인 글루텐에 대한 비정상적인 면역 반응을 특징으로 하는 복잡한 자가면역 질환입니다. 셀리악병의 복잡성은 유전적, 면역학적, 환경적 및 식이 요인의 복잡한 상호 작용에서 발생합니다.
이러한 합병증으로 인해 셀리악병은 이해하고, 진단하고, 관리하기 어려운 다면적이고 도전적인 자가면역 질환이 되었습니다. 따라서 셀리악병의 복잡성은 북미와 유럽 셀리악병 시장에 제약으로 작용할 것으로 예상됩니다.
기회
- 셀리악병에 대한 새로운 생물학적 치료법
셀리악병에 대한 새로운 생물학적 치료법은 평생 엄격한 글루텐 프리 식단인 현재의 치료 기준을 넘어서는 대체 치료법을 개발할 수 있는 유망한 길을 나타냅니다. 이러한 치료법은 아직 실험 단계에 있으며 임상 시험을 거치고 있지만, 셀리악병과 관련된 복잡성을 해결하고 이 자가면역 질환에 걸린 사람들에게 새로운 가능성을 제공할 잠재력을 가지고 있습니다.
셀리악병에 대한 생물학적 치료법의 개발은 근본적인 면역학적 메커니즘에 대한 이해의 증가와 이 자가면역 질환을 앓고 있는 개인의 삶의 질을 개선하기 위한 혁신적인 솔루션을 찾는 데 대한 헌신을 반영합니다. 연구가 진행됨에 따라 이러한 치료법은 엄격한 글루텐 없는 식단의 한계를 넘어 셀리악병을 관리하는 새로운 옵션을 제공할 수 있습니다. 따라서 셀리악병에 대한 새로운 생물학적 치료법은 북미와 유럽 셀리악병 시장에 기회가 될 것으로 예상됩니다.
도전
- 글루텐 없는 식단에 대한 환자 준수
환자가 글루텐 없는 식단을 고수하는 것은 셀리악병을 관리하는 데 중요하지만, 셀리악병 시장에는 과제를 안겨줍니다. 셀리악병 시장은 엄격한 글루텐 없는 식단이 현재 유일한 효과적인 치료법이기 때문에 과제에 직면해 있습니다. 제약 개입이나 대체 요법이 제한되어 있기 때문에 시장은 환자가 식이 제한을 고수하는 데 크게 의존합니다. 이러한 치료 다양성의 부족은 셀리악병 분야에서 운영되는 제약 회사의 수익 흐름을 제한합니다.
글루텐 없는 식단을 고수하는 환자는 셀리악병 시장에 도전 과제를 안겨주는데, 특히 치료 옵션의 제한, 경제적 고려 사항, 제약 개발에 미치는 영향 측면에서 그렇습니다. 따라서 글루텐 없는 식단을 고수하는 환자는 북미와 유럽 셀리악병 시장에 도전 과제로 작용할 것으로 예상됩니다.
최근 개발 사항
- 2022년 10월, Takeda Pharmaceutical Company Limited, Zedira 및 Dr. Falk Pharma GmbH는 셀리악병에 대한 2상 b 연구 약물인 ZED1227/TAK-227을 개발하기 위한 협력 및 라이선스 계약을 발표했습니다. 이 협력은 회사가 셀리악병 치료법을 내놓는 데 도움이 될 것입니다.
- 2020년 6월, Janssen Pharmaceuticals, Inc.는 Monash University와의 협력을 발표하고, 셀리악병의 근간이 되는 면역 메커니즘에 대한 이해를 높이고 새로운 진단 및 치료 방법의 개발을 알리기 위한 다년간의 연구에 서명했습니다. 이 협력은 주요 연구원과 산업 파트너를 모아 셀리악병을 예방하고 치료하는 혁신적인 면역 치료제를 개발하기 위해 이 주요 건강 문제를 해결합니다.
북미 및 유럽 셀리악병 시장 범위
북미와 유럽의 셀리악병 시장은 치료 유형, 진단, 질병 유형, 약물 유형, 처방 유형, 복용 형태, 투여 경로, 인구 유형, 최종 사용자 및 유통 채널을 기준으로 9개의 주요 세그먼트로 분류됩니다. 세그먼트 간 성장을 통해 틈새 시장의 성장과 시장에 접근하는 전략을 분석하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하는 데 도움이 됩니다.
치료 유형
- 코르티코스테로이드
- 면역억제제
- 기타
치료 유형을 기준으로 시장은 코르티코스테로이드, 면역억제제 및 기타로 구분됩니다 .
질병 유형
- 내성성 셀리악병
- 포진성 피부염
- 잠재적인 셀리악병
- 고전적 셀리악병
- 비전통적 셀리악병
질병 유형을 기준으로 시장은 내성 셀리악병, 피부염 포진성 셀리악병, 잠재적 셀리악병, 전형적 셀리악병, 비전형적 셀리악병으로 구분됩니다.
약물 유형
- 제네릭
- 브랜드화
약물 유형을 기준으로 시장은 브랜드 약물과 제네릭 약물로 구분됩니다.
처방 유형
- 처방
- 카운터 위
처방 유형을 기준으로 시장은 처방약과 일반의약품으로 구분됩니다.
투여 형태
- 태블릿
- 캡슐
- 주사
- 다른
복용 형태를 기준으로 시장은 정제, 캡슐, 주사제 및 기타로 구분됩니다.
투여 경로
- 경구
- 정맥
- 뉴스 영화
투여 경로를 기준으로 시장은 경구, 정맥 주사, 국소로 구분됩니다.
인구 유형
- 성인
- 어린이들
- 노인
인구 유형을 기준으로 시장은 성인, 어린이, 노인으로 구분됩니다.
최종 사용자
- 병원
- 클리닉
- 홈 케어 설정
- 기타
최종 사용자를 기준으로 시장은 병원, 진료소, 가정 간병 시설 및 기타로 구분됩니다.
유통 채널
- 병원 약국
- 소매 약국
- 온라인 약국
- 기타
유통 채널을 기준으로 시장은 병원 약국, 소매 약국, 온라인 약국 및 기타로 구분됩니다.
북미 및 유럽 셀리악병 시장 지역 분석/통찰력
위에 언급된 대로 국가, 치료 유형, 진단, 질병 유형, 약물 유형, 처방 유형, 복용 형태, 투여 경로, 인구 유형, 최종 사용자 및 유통 채널별로 시장을 분석하고 시장 규모에 대한 통찰력과 추세를 제공합니다.
이 시장 보고서에 포함된 국가로는 미국, 캐나다, 멕시코, 독일, 프랑스, 이탈리아, 스페인, 영국, 스위스, 네덜란드, 러시아, 터키, 폴란드, 스웨덴, 벨기에, 덴마크, 핀란드, 노르웨이 및 기타 유럽 국가가 있습니다.
미국 지역은 이 지역의 강력한 시장 참여자로 인해 시장을 지배할 것으로 예상됩니다. 독일 지역은 셀리악병의 높은 유병률과 진보된 의료 인프라로 인해 시장을 지배할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 북미 및 유럽 셀리악병 시장 점유율 분석
북미 및 유럽 셀리악병 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 승인, 제품 폭 및 호흡, 응용 프로그램 우세, 제품 유형 수명선 곡선입니다. 제공된 위의 데이터 포인트는 회사가 북미 및 유럽 셀리악병 시장에 집중하는 것과만 관련이 있습니다.
북미 및 유럽 셀리악병 시장의 주요 기업으로는 Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals(Bausch Health Companies Inc.의 자회사), Tillotts Pharma AG, GSK plc., ImmunogenX, Inc., Janssen Pharmaceuticals, Inc.(Johnson & Johnson Services, Inc.의 자회사), Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., AstraZeneca, Novartis AG, AdvaCare Pharma, ANOKION, Topas Therapeutics, Immunic Therapeutics, Equillium Bio 등이 있습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TREATMENT TYPE LIFELINE CURVE FOR THE NORTH AMERICA CELIAC DISEASE MARKET
2.8 TREATMENT TYPE LIFELINE CURVE THE EUROPE CELIAC DISEASE MARKET
2.9 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.1 DBMR MARKET POSITION GRID
2.11 MARKET END USER COVERAGE GRID
2.12 VENDOR SHARE ANALYSIS
2.13 SECONDARY SOURCES
2.14 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS 5 FORCES
4.3 EPIDEMIOLOGY
5 PIPELINE ANALYSIS
6 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, REGULATORY FRAMEWORK
6.1 REGULATIONS IN NORTH AMERICA
6.1.1 U.S.
6.1.2 CANADA
6.2 REGULATIONS IN EUROPE
6.2.1 EUROPEAN UNION (EU)
6.2.2 U.K.
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF CELIAC DISEASE
7.1.2 RISING CONSUMPTION OF GLUTEN-CONTAINING PRODUCTS
7.1.3 INCREASING RESEARCH AND DEVELOPMENT FOR CELIAC DISEASE TREATMENTS
7.1.4 GROWING AWARENESS ABOUT CELIAC DISEASE
7.2 RESTRAINTS
7.2.1 COMPLEXITY OF CELIAC DISEASE
7.2.2 LIMITED TREATMENT OPTIONS FOR CELIAC DISEASE
7.3 OPPORTUNITIES
7.3.1 EMERGING BIOLOGICAL THERAPIES FOR CELIAC DISEASE
7.3.2 RISING ADVANCEMENTS IN DIAGNOSTIC APPROACHES OF CELIAC DISEASE
7.3.3 STRATEGIC COLLABORATION FOR COMMERCIALIZATION OF NOVEL THERAPIES FOR CELIAC DISEASE
7.4 CHALLENGES
7.4.1 PATIENT ADHERENCE TO GLUTEN-FREE DIET
7.4.2 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS USED FOR CELIAC DISEASE TREATMENT
8 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY TREATMENT TYPE
8.1 OVERVIEW
8.2 CORTICOSTERIODS
8.2.1 PREDNISONE
8.2.2 .BUDESONIDE
8.2.3 BETAMETHASONE
8.2.4 CLOBETASONE BUTYRATE
8.2.5 OTHERS
8.3 IMMUNOSUPPRESSANTS
8.3.1 AZATHIOPRINE
8.3.2 INFLIXIMAB
8.3.3 CYCLOSPORINE
8.3.4 CLADRIBINE
8.3.5 OTHERS
8.4 OTHERS
9 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 REFRACTORY CELIAC DISEASE
9.2.1 TYPE I
9.2.2 TYPE II
9.3 DERMATITIS HERPETIFORMIS
9.4 POTENTIAL CELIAC DISEASE
9.5 CLASSICAL CELIAC DISEASE
9.6 NON-CLASSICAL CELIAC DISEASE
10 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DRUG TYPE
10.1 OVERVIEW
10.2 GENERICS
10.3 BRANDED
11 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE
11.1 OVERVIEW
11.2 PRESCRIPTION
11.3 OVER THE COUNTER
12 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DOSAGE FORM
12.1 OVERVIEW
12.2 TABLET
12.3 CAPSULES
12.4 INJECTIONS
12.5 OTHER
13 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 ORAL
13.2.1 TABLET
13.2.2 CAPSULES
13.2.3 OTHERS
13.3 INTRAVENOUS
13.4 TOPICAL
14 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY POPULATION TYPE
14.1 OVERVIEW
14.2 ADULTS
14.2.1 FEMALE
14.2.2 MALE
14.3 CHILDREN
14.4 GERIATRIC
14.4.1 FEMALE
14.4.2 MALE
15 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 CLINICS
15.4 HOME CARE SETTINGS
15.5 OTHERS
16 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACY
16.3 RETAIL PHARMACY
16.4 ONLINE PHARMACY
16.5 OTHERS
17 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY GEOGRAPHY
17.1 NORTH AMERICA
17.1.1 U.S.
17.1.2 CANADA
17.1.3 MEXICO
17.2 EUROPE
17.2.1 GERMANY
17.2.2 FRANCE
17.2.3 ITALY
17.2.4 SPAIN
17.2.5 U.K.
17.2.6 SWITZERLAND
17.2.7 NETHERLANDS
17.2.8 RUSSIA
17.2.9 TURKEY
17.2.10 POLAND
17.2.11 SWEDEN
17.2.12 BELGIUM
17.2.13 DENMARK
17.2.14 FINLAND
17.2.15 NORWAY
17.2.16 REST OF EUROPE
18 NORTH AMERICA CELIAC DISEASE MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
19 EUROPE CELIAC DISEASE MARKET: COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: EUROPE
20 SWOT ANALYSIS
21 COMPANY PROFILES
21.1 GSK PLC.
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 PRODUCT PORTFOLIO
21.1.4 RECENT DEVELOPMENT
21.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 PRODUCT PORTFOLIO
21.2.4 RECENT DEVELOPMENT
21.3 PFIZER INC.
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 PRODUCT PORTFOLIO
21.3.4 RECENT DEVELOPMENT
21.4 TEVA PHARMACEUTICALS USA, INC.
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 PRODUCT PORTFOLIO
21.4.4 RECENT DEVELOPMENT
21.5 NOVARTIS AG
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 PRODUCT PORTFOLIO
21.5.4 RECENT DEVELOPMENT
21.6 ADVACARE PHARMA
21.6.1 COMPANY SNAPSHOT
21.6.2 PRODUCT PORTFOLIO
21.6.3 RECENT DEVELOPMENT
21.7 AMGEN INC.
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENT
21.8 ANOKION
21.8.1 COMPANY SNAPSHOT
21.8.2 PRODUCT PORTFOLIO
21.8.3 RECENT DEVELOPMENT
21.9 EQUILLIUM BIO.
21.9.1 COMPANY SNAPSHOT
21.9.2 PRODUCT PORTFOLIO
21.9.3 RECENT DEVELOPMENT
21.1 IMMUNIC THERAPEUTICS
21.10.1 COMPANY SNAPSHOT
21.10.2 PRODUCT PORTFOLIO
21.10.3 RECENT DEVELOPMENT
21.11 IMMUNOGENX, INC.
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENT
21.12 SALIX PHARMACEUTICALS (SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS OF PARENT COMPANY
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENT
21.13 TAKEDA PHARMACEUTICAL COMPANY LIMITED
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENT
21.14 TILLOTTS PHARMA AG
21.14.1 COMPANY SNAPSHOT
21.14.2 PRODUCT PORTFOLIO
21.14.3 RECENT DEVELOPMENT
21.15 TOPAS THERAPEUTICS
21.15.1 COMPANY SNAPSHOT
21.15.2 PRODUCT PORTFOLIO
21.15.3 RECENT DEVELOPMENT
22 QUESTIONNAIRE
23 RELATED REPORTS
표 목록
TABLE 1 PIPELINE ANALYSIS FOR NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET
TABLE 2 NORTH AMERICA CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 3 EUROPE CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 4 NORTH AMERICA CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 5 NORTH AMERICA CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 6 EUROPE CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 7 EUROPE CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 8 NORTH AMERICA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 9 NORTH AMERICA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 10 EUROPE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 11 EUROPE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 12 NORTH AMERICA CELIAC DISEASE MARKET, BY DISEASE TYPE, 2022-2031 (USD THOUSAND)
TABLE 13 EUROPE CELIAC DISEASE MARKET, BY DISEASE TYPE, 2022-2031 (USD THOUSAND)
TABLE 14 NORTH AMERICA REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 15 EUROPE REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 16 NORTH AMERICA CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 17 EUROPE CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 18 NORTH AMERICA CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 19 EUROPE CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 20 NORTH AMERICA CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 21 EUROPE CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 22 NORTH AMERICA CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 23 EUROPE CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 24 NORTH AMERICA CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 25 EUROPE CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)
TABLE 26 NORTH AMERICA CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 27 EUROPE CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 28 NORTH AMERICA ADULTS IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 29 EUROPE ADULTS IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 30 NORTH AMERICA GERIATRIC IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 31 EUROPE GERAITRIC IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 32 NORTH AMERICA CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 33 EUROPE CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 34 NORTH AMERICA CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 35 EUROPE CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 36 NORTH AMERICA CELIAC DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 37 U.S. CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 38 U.S. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 39 U.S. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 40 U.S. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 41 U.S. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 42 U.S. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 43 U.S. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 44 U.S. CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 45 U.S. REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 46 U.S. CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 47 U.S. CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 48 U.S. CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 49 U.S. CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 50 U.S. ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 51 U.S. CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 52 U.S. ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 53 U.S. GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 U.S. CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 55 U.S. CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 56 CANADA CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 57 CANADA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 58 CANADA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 59 CANADA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 60 CANADA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 61 CANADA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 62 CANADA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 63 CANADA CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 64 CANADA REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 CANADA CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 66 CANADA CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 67 CANADA CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 68 CANADA CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 69 CANADA ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 70 CANADA CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 71 CANADA ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 72 CANADA GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 73 CANADA CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 74 CANADA CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 75 MEXICO CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 MEXICO CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 77 MEXICO CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 78 MEXICO CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 79 MEXICO IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 80 MEXICO IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 81 MEXICO IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 82 MEXICO CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 83 MEXICO REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 84 MEXICO CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 85 MEXICO CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 86 MEXICO CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 87 MEXICO CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 88 MEXICO ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 89 MEXICO CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 MEXICO ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 91 MEXICO GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 92 MEXICO CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 93 MEXICO CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 94 EUROPE CELIAC DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 95 GERMANY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 GERMANY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 97 GERMANY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 98 GERMANY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 99 GERMANY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 100 GERMANY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 101 GERMANY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 102 GERMANY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 103 GERMANY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 104 GERMANY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 105 GERMANY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 106 GERMANY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 107 GERMANY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 108 GERMANY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 109 GERMANY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 110 GERMANY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 111 GERMANY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 112 GERMANY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 113 GERMANY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 114 FRANCE CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 115 FRANCE CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 116 FRANCE CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 117 FRANCE CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 118 FRANCE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 119 FRANCE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 120 FRANCE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 121 FRANCE CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 122 FRANCE REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 123 FRANCE CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 124 FRANCE CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 125 FRANCE CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 126 FRANCE CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 127 FRANCE ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 128 FRANCE CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 129 FRANCE ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 130 FRANCE GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 131 FRANCE CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 132 FRANCE CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 133 ITALY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 134 ITALY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 135 ITALY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 136 ITALY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 137 ITALY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 138 ITALY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 139 ITALY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 140 ITALY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 141 ITALY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 142 ITALY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 143 ITALY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 144 ITALY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 145 ITALY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 146 ITALY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 147 ITALY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 148 ITALY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 149 ITALY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 150 ITALY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 151 ITALY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 152 SPAIN CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 153 SPAIN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 154 SPAIN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 155 SPAIN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 156 SPAIN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 157 SPAIN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 158 SPAIN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 159 SPAIN CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 160 SPAIN REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 161 SPAIN CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 162 SPAIN CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 163 SPAIN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 164 SPAIN CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 165 SPAIN ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 166 SPAIN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 167 SPAIN ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 168 SPAIN GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 169 SPAIN CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 170 SPAIN CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 171 U.K. CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 172 U.K. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 173 U.K. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 174 U.K. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 175 U.K. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 176 U.K. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 177 U.K. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 178 U.K. CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 179 U.K. REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 180 U.K. CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 181 U.K. CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 182 U.K. CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 183 U.K. CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 184 U.K. ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 185 U.K. CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 186 U.K. ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 187 U.K. GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 188 U.K. CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 189 U.K. CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 190 SWITZERLAND CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 191 SWITZERLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 192 SWITZERLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 193 SWITZERLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 194 SWITZERLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 195 SWITZERLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 196 SWITZERLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 197 SWITZERLAND CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 198 SWITZERLAND REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 199 SWITZERLAND CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 200 SWITZERLAND CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 201 SWITZERLAND CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 202 SWITZERLAND CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 203 SWITZERLAND ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 204 SWITZERLAND CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 205 SWITZERLAND ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 206 SWITZERLAND GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 207 SWITZERLAND CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 208 SWITZERLAND CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 209 NETHERLANDS CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 210 NETHERLANDS CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 211 NETHERLANDS CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 212 NETHERLANDS CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 213 NETHERLANDS IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 214 NETHERLANDS IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 215 NETHERLANDS IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 216 NETHERLANDS CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 217 NETHERLANDS REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 218 NETHERLANDS CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 219 NETHERLANDS CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 220 NETHERLANDS CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 221 NETHERLANDS CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 222 NETHERLANDS ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 223 NETHERLANDS CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 224 NETHERLANDS ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 225 NETHERLANDS GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 226 NETHERLANDS CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 227 NETHERLANDS CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 228 RUSSIA CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 229 RUSSIA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 230 RUSSIA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 231 RUSSIA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 232 RUSSIA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 233 RUSSIA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 234 RUSSIA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 235 RUSSIA CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 236 RUSSIA REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 237 RUSSIA CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 238 RUSSIA CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 239 RUSSIA CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 240 RUSSIA CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 241 RUSSIA ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 242 RUSSIA CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 243 RUSSIA ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 244 RUSSIA GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 245 RUSSIA CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 246 RUSSIA CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 247 TURKEY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 248 TURKEY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 249 TURKEY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 250 TURKEY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 251 TURKEY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 252 TURKEY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 253 TURKEY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 254 TURKEY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 255 TURKEY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 256 TURKEY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 257 TURKEY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 258 TURKEY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 259 TURKEY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 260 TURKEY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 261 TURKEY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 262 TURKEY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 263 TURKEY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 264 TURKEY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 265 TURKEY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 266 POLAND CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 267 POLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 268 POLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 269 POLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 270 POLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 271 POLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 272 POLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 273 POLAND CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 274 POLAND REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 275 POLAND CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 276 POLAND CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 277 POLAND CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 278 POLAND CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 279 POLAND ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 280 POLAND CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 281 POLAND ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 282 POLAND GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 283 POLAND CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 284 POLAND CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 285 SWEDEN CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 286 SWEDEN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 287 SWEDEN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 288 SWEDEN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 289 SWEDEN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 290 SWEDEN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 291 SWEDEN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 292 SWEDEN CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 293 SWEDEN REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 294 SWEDEN CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 295 SWEDEN CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 296 SWEDEN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 297 SWEDEN CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 298 SWEDEN ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 299 SWEDEN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 300 SWEDEN ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 301 SWEDEN GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 302 SWEDEN CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 303 SWEDEN CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 304 BELGIUM CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 305 BELGIUM CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 306 BELGIUM CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 307 BELGIUM CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 308 BELGIUM IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 309 BELGIUM IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 310 BELGIUM IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 311 BELGIUM CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 312 BELGIUM REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 313 BELGIUM CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 314 BELGIUM CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 315 BELGIUM CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 316 BELGIUM CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 317 BELGIUM ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 318 BELGIUM CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 319 BELGIUM ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 320 BELGIUM GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 321 BELGIUM CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 322 BELGIUM CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 323 DENMARK CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 324 DENMARK CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 325 DENMARK CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 326 DENMARK CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 327 DENMARK IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 328 DENMARK IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 329 DENMARK IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 330 DENMARK CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 331 DENMARK REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 332 DENMARK CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 333 DENMARK CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 334 DENMARK CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 335 DENMARK CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 336 DENMARK ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 337 DENMARK CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 338 DENMARK ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 339 DENMARK GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 340 DENMARK CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 341 DENMARK CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 342 FINLAND CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 343 FINLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 344 FINLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 345 FINLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 346 FINLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 347 FINLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 348 FINLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 349 FINLAND CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 350 FINLAND REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 351 FINLAND CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 352 FINLAND CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 353 FINLAND CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 354 FINLAND CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 355 FINLAND ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 356 FINLAND CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 357 FINLAND ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 358 FINLAND GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 359 FINLAND CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 360 FINLAND CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 361 NORWAY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
TABLE 362 NORWAY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 363 NORWAY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)
TABLE 364 NORWAY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 365 NORWAY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 366 NORWAY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)
TABLE 367 NORWAY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)
TABLE 368 NORWAY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)
TABLE 369 NORWAY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 370 NORWAY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 371 NORWAY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)
TABLE 372 NORWAY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 373 NORWAY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 374 NORWAY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 375 NORWAY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)
TABLE 376 NORWAY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 377 NORWAY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 378 NORWAY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 379 NORWAY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 380 REST OF EUROPE CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)
그림 목록
FIGURE 1 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA CELIAC DISEASE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE CELIAC DISEASE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 6 NORTH AMERICA CELIAC DISEASE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 7 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA CELIAC DISEASE MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE CELIAC DISEASE MARKET: DBMR MARKET POSITION GRID
FIGURE 10 NORTH AMERICA CELIAC DISEASE MARKET: MARKET END USER COVERAGE GRID
FIGURE 11 EUROPE CELIAC DISEASE MARKET: MARKET END USER COVERAGE GRID
FIGURE 12 NORTH AMERICA CELIAC DISEASE MARKET: VENDOR SHARE ANALYSIS
FIGURE 13 EUROPE CELIAC DISEASE MARKET: VENDOR SHARE ANALYSIS
FIGURE 14 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: SEGMENTATION
FIGURE 15 THE INCREASING PREVALENCE OF CELIAC DISEASE IS DRIVING THE GROWTH OF THE NORTH AMERICA CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 16 RISING CONSUMPTION OF GLUTEN-CONTAINING PRODUCTS IS DRIVING THE GROWTH OF THE EUROPE CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 17 CORTICOSTEROIDS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 AND 2031
FIGURE 18 CARTICOSTEROIDS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 AND 2031
FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET
FIGURE 20 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2023
FIGURE 21 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2024-2031 (USD THOUSAND)
FIGURE 22 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, CAGR (2024-2031)
FIGURE 23 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 24 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2023
FIGURE 25 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2024-2031 (USD THOUSAND)
FIGURE 26 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, CAGR (2024-2031)
FIGURE 27 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 28 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, 2023
FIGURE 29 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, 2024-2031 (USD THOUSAND)
FIGURE 30 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, CAGR (2024-2031)
FIGURE 31 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 32 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, 2023
FIGURE 33 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, 2024-2031 (USD THOUSAND)
FIGURE 34 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, CAGR (2024-2031)
FIGURE 35 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 36 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, 2023
FIGURE 37 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)
FIGURE 38 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 39 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 40 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, 2023
FIGURE 41 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)
FIGURE 42 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 43 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 44 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2023
FIGURE 45 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2024-2031 (USD THOUSAND)
FIGURE 46 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, CAGR (2024-2031)
FIGURE 47 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, LIFELINE CURVE
FIGURE 48 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2023
FIGURE 49 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2024-2031 (USD THOUSAND)
FIGURE 50 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, CAGR (2024-2031)
FIGURE 51 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, LIFELINE CURVE
FIGURE 52 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, 2023
FIGURE 53 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, 2024-2031 (USD THOUSAND)
FIGURE 54 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, CAGR (2024-2031)
FIGURE 55 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 56 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, 2023
FIGURE 57 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, 2024-2031 (USD THOUSAND)
FIGURE 58 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, CAGR (2024-2031)
FIGURE 59 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 60 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 61 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)
FIGURE 62 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 63 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 64 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 65 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)
FIGURE 66 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 67 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 68 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, 2023
FIGURE 69 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, 2024-2031 (USD THOUSAND)
FIGURE 70 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, CAGR (2024-2031)
FIGURE 71 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 72 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, 2023
FIGURE 73 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, 2024-2031 (USD THOUSAND)
FIGURE 74 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, CAGR (2024-2031)
FIGURE 75 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 76 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, 2023
FIGURE 77 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 78 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, CAGR (2024-2031)
FIGURE 79 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, LIFELINE CURVE
FIGURE 80 EUROPE CELIAC DISEASE MARKET: BY END USER, 2023
FIGURE 81 EUROPE CELIAC DISEASE MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 82 EUROPE CELIAC DISEASE MARKET: BY END USER, CAGR (2024-2031)
FIGURE 83 EUROPE CELIAC DISEASE MARKET: BY END USER, LIFELINE CURVE
FIGURE 84 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 85 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 86 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 87 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 88 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 89 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 90 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 91 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 92 NORTH AMERICA CELIAC DISEASE MARKET: SNAPSHOT (2023)
FIGURE 93 EUROPE CELIAC DISEASE MARKET: SNAPSHOT (2023)
FIGURE 94 NORTH AMERICA CELIAC DISEASE MARKET: COMPANY SHARE 2023 (%)
FIGURE 95 EUROPE CELIAC DISEASE MARKET: COMPANY SHARE 2023 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
